In what kind of solid tumors can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations that may be missed by hotspot tests? (Korean)

In what kind of solid tumors can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations that may be missed by hotspot tests? (Korean)

In what kind of solid tumors, specifically NSCLC, can comprehensive genomic profiling/NGS make a difference in identifying patients with EGFR and other mutations—ALK, MET, ROS-1—that may be missed by hotspot tests?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Yonsei Cancer Center
Yonsei University College of Medicine J
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea